Emergent Biosolutions Inc. (NYSE:EBS) Receives $12.00 Average Price Target from Brokerages

Shares of Emergent Biosolutions Inc. (NYSE:EBS) have received a consensus rating of “Hold” from the five research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $12.00.

A number of equities research analysts have recently commented on the stock. Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday. HC Wainwright cut their price target on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Weiss Ratings cut shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Finally, UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday.

Insider Activity

In related news, Director Kathryn C. Zoon sold 17,202 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $8.40, for a total value of $144,496.80. Following the sale, the director owned 79,941 shares in the company, valued at approximately $671,504.40. This trade represents a 17.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Donald W. Degolyer sold 15,481 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $130,040.40. Following the completion of the sale, the director owned 129,721 shares in the company, valued at $1,089,656.40. This represents a 10.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 61,925 shares of company stock worth $518,312. Corporate insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On Emergent Biosolutions

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its holdings in Emergent Biosolutions by 22.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock worth $22,884,000 after purchasing an additional 504,553 shares during the last quarter. State Street Corp boosted its holdings in Emergent Biosolutions by 10.2% in the fourth quarter. State Street Corp now owns 2,696,375 shares of the biopharmaceutical company’s stock worth $33,327,000 after purchasing an additional 250,616 shares during the last quarter. Millennium Management LLC boosted its holdings in Emergent Biosolutions by 68.9% in the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after purchasing an additional 1,020,582 shares during the last quarter. American Century Companies Inc. boosted its holdings in Emergent Biosolutions by 3.9% in the third quarter. American Century Companies Inc. now owns 2,382,378 shares of the biopharmaceutical company’s stock worth $21,013,000 after purchasing an additional 90,216 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Emergent Biosolutions by 17.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,618,903 shares of the biopharmaceutical company’s stock worth $20,010,000 after purchasing an additional 237,153 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Trading Down 4.2%

NYSE:EBS opened at $8.08 on Tuesday. The company’s 50 day moving average price is $8.41 and its 200-day moving average price is $10.03. Emergent Biosolutions has a 52 week low of $5.61 and a 52 week high of $14.06. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10. The stock has a market cap of $417.08 million, a price-to-earnings ratio of -28.87 and a beta of 2.33.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The firm had revenue of $156.10 million for the quarter, compared to analysts’ expectations of $145.00 million.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.